Details for Patent: 8,846,628
✉ Email this page to a colleague
Which drugs does patent 8,846,628 protect, and when does it expire?
Patent 8,846,628 protects ONUREG and is included in one NDA.
This patent has ninety-nine patent family members in thirty-five countries.
Summary for Patent: 8,846,628
| Title: | Oral formulations of cytidine analogs and methods of use thereof |
| Abstract: | The present disclosure provides pharmaceutical compositions comprising cytidine analogs, for example, 5-azacytidine or decitabine, for oral administration, wherein the compositions release the cytidine analog, for example, 5-azacytidine or decitabine, substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein. |
| Inventor(s): | Etter; Jeffrey B. (Boulder, CO), Lai; Mei (Longmont, CO), Backstrom; Jay Thomas (Leawood, KS) |
| Assignee: | Celgene Corporation (Summit, NJ) |
| Application Number: | 12/466,213 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
More… ↓ |
Drugs Protected by US Patent 8,846,628
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol | ONUREG | azacitidine | TABLET;ORAL | 214120-001 | Sep 1, 2020 | RX | Yes | No | 8,846,628 | ⤷ Subscribe | Y | CONTINUED TREATMENT OF ADULTS WITH ACUTE MYELOID LEUKEMIA WHO ACHIEVED FIRST COMPLETE REMISSION (CR) OR CR WITH INCOMPLETE BLOOD COUNT RECOVERY FOLLOWING INTENSIVE INDUCTION CHEMOTHERAPY AND ARE NOT ABLE TO COMPLETE INTENSIVE CURATIVE THERAPY | ⤷ Subscribe | |||
| Bristol | ONUREG | azacitidine | TABLET;ORAL | 214120-002 | Sep 1, 2020 | RX | Yes | Yes | 8,846,628 | ⤷ Subscribe | Y | CONTINUED TREATMENT OF ADULTS WITH ACUTE MYELOID LEUKEMIA WHO ACHIEVED FIRST COMPLETE REMISSION (CR) OR CR WITH INCOMPLETE BLOOD COUNT RECOVERY FOLLOWING INTENSIVE INDUCTION CHEMOTHERAPY AND ARE NOT ABLE TO COMPLETE INTENSIVE CURATIVE THERAPY | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,846,628
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 071808 | ⤷ Subscribe | |||
| Australia | 2009246926 | ⤷ Subscribe | |||
| Australia | 2013202665 | ⤷ Subscribe | |||
| Australia | 2015202884 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
